title: Toxicity of sunitinib plus bevacizumab in renal cell carcinoma.
authors.forename: Brian I
authors.initials: BI
authors.lastname: Rini
authors.forename: Jorge A
authors.initials: JA
authors.lastname: Garcia
authors.forename: Matthew M
authors.initials: MM
authors.lastname: Cooney
authors.forename: Paul
authors.initials: P
authors.lastname: Elson
authors.forename: Allison
authors.initials: A
authors.lastname: Tyler
authors.forename: Kristi
authors.initials: K
authors.lastname: Beatty
authors.forename: Joseph
authors.initials: J
authors.lastname: Bokar
authors.forename: Percy
authors.initials: P
authors.lastname: Ivy
authors.forename: Helen X
authors.initials: HX
authors.lastname: Chen
authors.forename: Afshin
authors.initials: A
authors.lastname: Dowlati
authors.forename: Robert
authors.initials: R
authors.lastname: Dreicer
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects*; D000068258:Bevacizumab; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D015331:Cohort Studies; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000009:adverse effects; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011758:Pyrroles / Q000008:administration & dosage / Q000009:adverse effects; D000077210:Sunitinib
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007211:Indoles; D011758:Pyrroles; D000068258:Bevacizumab; D000077210:Sunitinib